公开(公告)号：US20230076197A1

公开(公告)日：2023-03-09

申请号：US17962560

申请日：2022-10-10

Applicant: SUN YAT-SEN UNIVERSITY

Inventor： Weiwei SU ,  Yonggang WANG ,  Peibo LI ,  Hongyu RAO ,  Hao WU

IPC: A61K36/185 ,  A61P31/14

Abstract: An application of HJT aqueous extract in the preparation of drugs against a Blue-ear disease is provided. For the first time, it is found in the present invention that HJT extract has a significant effect of preventing and treating the Blue-ear disease. Specifically, through experiments of qRT-PCR and immunofluorescence techniques, the present invention has proved that HJT extract can significantly inhibit infection and replication of PPRSV with significant antiviral effect, so that it is expected to become a new type of biologically active substance for prevention and treatment of Blue-ear disease. The product prepared by the method can be used as natural antiviral drugs for the prevention and treatment of the Blue-ear disease, realizes the comprehensive utilization of HJT plants, and improves its value, which has a good application prospect.

公开(公告)号：US20220362186A1

公开(公告)日：2022-11-17

申请号：US17274779

申请日：2020-02-01

Applicant: SUN YAT-SEN UNIVERSITY

Inventor： Hao WU ,  Taobin CHEN ,  Yonggang WANG ,  Weiwei SU

IPC: A61K31/192 ,  A61P31/04

Abstract: The present invention relates to new medicine application of p-hydroxyphenylpropionic acid. Experiments prove that p-hydroxyphenylpropionic acid has a remarkable pharmacological effect in inhibiting respiratory tract infection, particularly inhibiting pulmonary edema, inflammatory cell infiltration and cell apoptosis in lung injury and delaying lung function degradation of mice. Therefore, the present invention discloses the application of p-hydroxyphenylpropionic acid to prepare a medicine for preventing and treating respiratory tract infection, particularly pneumonia, pulmonary edema or pulmonary epithelial and/or endothelial cell necrosis in lung injury for the first time.

公开(公告)号：US20160303156A1

公开(公告)日：2016-10-20

申请号：US15100992

申请日：2015-08-28

Applicant: Sun Yat-sen University

Inventor： Weiwei SU ,  Haoyan JIAO ,  Yan LIAO ,  Peibo LI ,  Wei PENG ,  Yonggang WANG

IPC: A61K31/7048 ,  A61K9/48 ,  A61K9/20 ,  A61K31/495

CPC classification number: A61K31/7048 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/485 ,  A61K9/4866 ,  A61K31/495 ,  A61K2300/00

Abstract: A naringin composition and preparations thereof are provided. The pharmaceutical composition comprises naringin and levocetirizine hydrochloride, and preferably, 27.5-275 mg of naringin and 1.25-12.5 mg of levocetirizine hydrochloride, where the preferred weight ratio of naringin to levocetirizine hydrochloride is 20:1. The pharmaceutical composition has good curative effects on cough and sputum production originating from various causes and on cough variant asthma. The efficacy of the pharmaceutical composition is obviously superior to that of naringin or levocetirizine hydrochloride that is used alone.

Abstract translation: 提供了柚皮苷组合物及其制备方法。 药物组合物包含柚皮苷和盐酸左西替利嗪，优选27.5-275mg柚皮苷和1.25-12.5mg盐酸左西替利嗪，其中柚皮苷与盐酸左西替利嗪的优选重量比为20:1。 该药物组合物对源于各种原因的咳嗽和痰产生以及咳嗽变异型哮喘具有良好的疗效。 药物组合物的疗效明显优于单独使用的柚皮苷或盐酸左西替利嗪的疗效。